Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | PGR | P06401 | 6/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.32 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | ACLY | P53396 | 3/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.30 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4645004 | 0.89 | PGR (0.40) | PGRSLC22A12NR3C1NR3C2AR | |
| SCHEMBL2005661 | 0.72 | ADRA2C (0.38) | — | |
| SCHEMBL2005491 | 0.71 | SLC22A12 (0.47) | PGRSLC22A12NR3C1ACLYPARP14 | |
| SCHEMBL6389949 | 0.71 | SLC22A12 (0.47) | TTRALBPGRSLC22A12NR3C1 | |
| SCHEMBL15959190 | 0.70 | PGR (0.34) | PGRNR3C1NR3C2AR | |
| SCHEMBL17501363 | 0.69 | IRAK4 (0.42) | PGRSLC22A12HSD11B1 | |
| SCHEMBL954083 | 0.69 | ADRA2C (0.35) | PGRNR3C1NR3C2AR | |
| SCHEMBL22003181 | 0.69 | TTR (0.54) | TTRALB | |
| SCHEMBL23099521 | 0.68 | TTR (0.52) | TTRALB | |
| SCHEMBL19354876 | 0.68 | TTR (0.37) | TTRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960584-B2 | 3-(4-t-butyl-phenyl)-N-(4-methanesulfonylamino-benzyl)-2-methyl-acrylamide; pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane | AMOREPACIFIC CORPORATION (KR) | 2011-06-14 | — | — | US | disclosed |
| US-20080234383-A1 | Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same | AMOREPACIFIC CORPORATION (KR) | 2008-09-25 | — | — | US | disclosed |
| EP-1861358-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006101321-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST; AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234383-A1 | Novel Compounds, Isomer Thereof, or Pharmaceutically Acceptable Salts Thereof as Vanilloid Receptor Antagonist; and Pharmaceutical Compositions Containing the Same | TRPV1, TRPA1, TRPV5 | TTR 3575/4885ALB 4476/4885PGR 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.